Xtant Medical Holdings, Inc. (NYSEAMERICAN:XTNT) Short Interest Down 35.9% in February

Xtant Medical Holdings, Inc. (NYSEAMERICAN:XTNT) was the target of a significant decline in short interest in February. As of February 27th, there was short interest totaling 18,020 shares, a decline of 35.9% from the February 12th total of 28,112 shares. Based on an average daily volume of 79,625 shares, the short-interest ratio is presently 0.2 days. Approximately 0.0% of the shares of the company are sold short. Approximately 0.0% of the shares of the company are sold short. Based on an average daily volume of 79,625 shares, the short-interest ratio is presently 0.2 days.

Xtant Medical Stock Performance

Shares of Xtant Medical stock traded up $0.02 on Friday, hitting $0.62. The stock had a trading volume of 115,265 shares, compared to its average volume of 92,411. The company’s 50 day moving average price is $0.62 and its 200 day moving average price is $0.67. The stock has a market cap of $86.94 million, a price-to-earnings ratio of 62.16 and a beta of -0.30. The company has a current ratio of 2.21, a quick ratio of 1.06 and a debt-to-equity ratio of 0.35. Xtant Medical has a 52-week low of $0.34 and a 52-week high of $0.95.

Hedge Funds Weigh In On Xtant Medical

A number of hedge funds have recently modified their holdings of XTNT. Wiregrass Investment Management LLC purchased a new stake in Xtant Medical in the 4th quarter valued at $81,000. Renaissance Technologies LLC grew its position in Xtant Medical by 28.8% during the 4th quarter. Renaissance Technologies LLC now owns 919,860 shares of the medical device company’s stock worth $721,000 after purchasing an additional 205,945 shares during the last quarter. Tradition Wealth Management LLC acquired a new position in Xtant Medical in the fourth quarter valued at $79,000. Hillsdale Investment Management Inc. purchased a new stake in shares of Xtant Medical in the fourth quarter valued at about $284,000. Finally, Nano Cap New Millennium Growth Fund L P acquired a new stake in shares of Xtant Medical during the fourth quarter worth about $220,000. 69.33% of the stock is currently owned by hedge funds and other institutional investors.

Xtant Medical Company Profile

Xtant Medical, Inc is a medical technology company focused on the development, manufacturing and distribution of bone graft, spine biologics and related implantable medical devices. The company’s product portfolio is designed to address critical needs in spinal fusion, orthopedics and trauma surgery by providing a range of solutions that promote bone growth, structural support and patient recovery.

The company’s offerings include an array of bone graft substitutes – such as demineralized bone matrix putties and fibers – interbody fusion devices, spinal fixation systems and biologic agents.